Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Fineline Cube Feb 4, 2026
Company Deals Drug

Akeso Licenses Yixining to Jumpcan for PCSK9 Promotion in China

Fineline Cube Feb 4, 2026
Company Deals

Grand Pharmaceutical to Acquire API Firms for RMB 316 Million

Fineline Cube Feb 4, 2026
Company Deals

Simcere Receives $40M Milestone from AbbVie for Trispecific Myeloma Drug

Fineline Cube Feb 4, 2026
Company Deals

Medtronic to Acquire CathWorks for $585M, Expand AI-Based FFRangio System

Fineline Cube Feb 4, 2026
Policy / Regulatory

NMPA Releases 101st Batch of Generic Reference Drugs

Fineline Cube Feb 2, 2026
Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Fineline Cube Feb 4, 2026
Company Drug

Marubeni Launches Xenleta in China After Complex Licensing Journey

Fineline Cube Feb 4, 2026
Company Drug

China Grand Pharmaceutical Receives FDA Approval for Post-Surgical Ophthalmic Drug GPN00833

Fineline Cube Mar 8, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced that it has...

Company Drug

Shanghai Fosun Pharma Gets NMPA Green Light for XS-02 Solid Tumor Clinical Study

Fineline Cube Mar 8, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

Everest Medicines to Establish Integrated Kidney Disease Diagnosis and Treatment Ecosystem

Fineline Cube Mar 7, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical company, is set to collaborate with partners to...

Company Drug

Boehringer Ingelheim’s Spevigo Receives NMPA Approval for GPP Treatment in China

Fineline Cube Mar 7, 2024

German pharmaceutical giant Boehringer Ingelheim (BI) has announced that it has received marketing approval from...

Company Deals

Zylox-Tonbridge Medical Technology Secures Licensing Deal with Avinger to Boost Device Portfolio

Fineline Cube Mar 7, 2024

Zylox-Tonbridge Medical Technology (HKG: 2190), a China-based developer of nerve and peripheral vascular interventional devices,...

Company Deals

BeiGene Subsidiary Pi Health Cayman to be Merged in Deal Valued at $41.8 Million

Fineline Cube Mar 7, 2024

BeiGene (NASDAQ: BGNE) has announced that Delaware-based Pi Health Inc. is set to absorb and...

Company Drug

Luye Pharma Launches Small-Cell Lung Cancer Treatment Zepzelca in Hong Kong and Macau

Fineline Cube Mar 7, 2024

Luye Pharma Group (HKG: 2186), a China-based pharmaceutical company, has announced the official market launch...

Company Deals

Proviva Therapeutics Secures $18 Million in Series A Financing to Advance PTX-912

Fineline Cube Mar 7, 2024

Proviva Therapeutics, a Shanghai-based clinical-stage biotechnology company, has reportedly secured USD 18 million in a...

Legal / IP Policy / Regulatory

US Senate Committee Backs Bill to Restrict Chinese Biotechnology Firms’ Access to American Genetic Data

Fineline Cube Mar 7, 2024

The U.S. Senate’s homeland security committee has voted 11-1 in favor of the Prohibiting Foreign...

Company Drug

CARsgen Launches BCMA-Targeted CAR-T Therapy in China with High Price Point

Fineline Cube Mar 7, 2024

China-based CAR-T cell therapy specialist CARsgen Therapeutics Holdings Ltd. (HKG: 2171) has launched its BCMA-targeted...

Company Drug

Xian Janssen’s Tremfya Heads for Priority Review in China for Crohn’s Disease Treatment

Fineline Cube Mar 7, 2024

The Center for Drug Evaluation (CDE) has indicated that Xian Janssen Pharmaceutical’s Tremfya (guselkumab), an...

Company Drug

EMA Reviews J&J’s Darzalex Subcutaneous Formulation for Newly Diagnosed Multiple Myeloma

Fineline Cube Mar 7, 2024

The European Medicines Agency (EMA) has this week received an indication extension filing from Johnson...

Company Drug

Gilead and MSD Report Positive Interim Data for Once-Weekly HIV Treatment in Phase II Trial

Fineline Cube Mar 7, 2024

Gilead Sciences Inc. (NASDAQ: GILD) and Merck & Co., Inc., known as MSD (NYSE: MRK),...

Company Deals

Gilead and Merus Form Strategic Oncology Alliance to Develop Trispecific T-Cell Engagers

Fineline Cube Mar 7, 2024

Gilead Sciences Inc., (NASDAQ: GILD), has entered into a strategic partnership with Netherlands-based Merus N.V....

Company Drug

Henlius Biotech’s HER2 Targeting Biosimilar Secures Thai and Philippine Approvals

Fineline Cube Mar 7, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696) a leading China-based biotech firm, has announced that its...

Company Deals

Lee’s Pharmaceutical Secures Malaysian Distribution for Generic Glaucoma Treatment

Fineline Cube Mar 7, 2024

Lee’s Pharmaceutical Holdings Ltd., (HKG: 0950), a China-based pharmaceutical company, has announced through its subsidiary...

Company

Sino Medical Sciences Gains Pakistani Nod for SC HONKYTONK and NC ROCKSTAR Catheters

Fineline Cube Mar 6, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a Chinese medical device company, has announced that...

Company Drug

Duality Biologics’ DB-1303 on Track for Breakthrough Designation for HER2+ Endometrial Cancer

Fineline Cube Mar 6, 2024

The Center for Drug Evaluation (CDE) website has indicated that DB-1303, a HER2 targeted antibody...

Company Deals

Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform

Fineline Cube Mar 6, 2024

China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...

Company Deals Digital

ClouDr Inks Deal with CR Sanjiu to Boost Hospital Sales of Cardiovascular Medicine

Fineline Cube Mar 6, 2024

Hangzhou Kang Ming Information Technology Co., Ltd, (HKG: 9955) trading under the moniker “ClouDr”, has...

Posts pagination

1 … 346 347 348 … 619

Recent updates

  • Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows
  • Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump
  • Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial
  • Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa
  • Marubeni Launches Xenleta in China After Complex Licensing Journey
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows

Others

Merck Keytruda Revenue Drives $65.5B Sales Despite Gardasil China Slump

Company Drug

Hualan Biological’s HL08 GLP-1 Drug Gets NMPA Nod for Obesity Trial

Company Deals

Bio-Thera Licenses Keytruda Biosimilar BAT3306 to Avalon for Middle East & North Africa

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.